Comparison the efficacy of Triamcinolone Acetonide 0.1 % in Orabase with it's nanoliposomal carriers formulation on oral Lichen Planus patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2014080416090N5

Enrollment

Registered

2014-10-04

Start date

2013-11-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lichen Planus. Papulosquamous disorders

Interventions

Intervention 1: Intervention group: Triamcinolone Acetonide 0.1% with nanoliposomal carriers in Orabase, Oral paste, three times a day for a month. Intervention 2: Control group: Triamcinolone Acetoni

Treatment - Drugs

Intervention group: Triamcinolone Acetonide 0.1% with nanoliposomal carriers in Orabase, Oral paste, three times a day for a month

Control group: Triamcinolone Acetonide 0.1% in Orabase, Oral paste, three times a day for a month

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion Criteria: All referral patients to Oral Medicine Department of Dental Branch, Islamic Azad University of Tehran with symptomatic oral lesions suspected of Lichen Planus; with confirmed diagnosis clinically and histologically of atrophic or erosive oral Lichen Planus. Exclusion Criteria: presence of dysplasia on histological examination; pregnancy; nursing; dysfunction of immune system(organ transplantation, lupus erythematous, ulcerative colitis); hematologic diseases; systemic diseases; history of systemic or topical corticosteroid therapy for Lichen Planus in the past month; Lichenoid reactions due to drug use or restorative materials.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Pain intensity. Timepoint: before treatment, 1, 2 and 4 weeks after treatment. Method of measurement: Visual Analogue Scale.;Area of the erythematous-erosive lesion. Timepoint: before treatment, 1, 2 and 4 weeks after treatment. Method of measurement: mm2.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Arash Azizi

Dental Branch Islamic Azad University of Tehran

a_azizi@dentaliau.ac.ir+98 21 2258 0925

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026